Intas Pharmaceuticals Reports Retrospective Study Results of Razumab (biosimilar, ranibizumab) for the Treatment of Retinopathy of Prematurity
Shots:
- The retrospective study from India showed that Razumab, a ranibizumab biosimilar was safe & effective to use in infant patients. Among the results from 118 eyes of 59 infants with a median gestational age of 30wks, APROP was found in 28 eyes (24%) of 14 babies, stage 3 disease in zone 1 in another 28 eyes (24%) & 62 eyes (52%) had stage 3 ROP in zone 2 posterior region
- Complete resolution of ROP along with complete vascularization was seen in 22 eyes (19%) at a median of 55 days, 35% showed a recurrence in neovascularization & received repeat inj. at a median of 51 days post-inj.
- 45% of eyes did not develop recurrence or complete vascularization after 6wks. and required laser treatment to the residual avascular retina, no infants died or experienced TRAEs
Ref: The Center For Biosimilar | Image: Intas
Related News:- Intas Pharmaceuticals Reports Real-World Study Results of Razumab (biosimilar, ranibizumab) for Polypoidal Choroidal Vasculopathy
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
